{"drugs":["Micardis","Telmisartan"],"mono":{"0":{"id":"924826-s-0","title":"Generic Names","mono":"Telmisartan"},"1":{"id":"924826-s-1","title":"Dosing and Indications","sub":[{"id":"924826-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Cardiovascular event risk, Reduction:<\/b> 80 mg ORALLY once daily<\/li><li><b>Hypertension:<\/b> initial, 40 mg ORALLY once daily; dose range, 20 to 80 mg ORALLY once daily<\/li><\/ul>"},{"id":"924826-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy not established in pediatric patients "},{"id":"924826-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>hepatic impairment, biliary obstruction:<\/b> provide close monitoring<\/li><li><b>volume depletion, dialysis patients:<\/b> provide close monitoring for blood pressure<\/li><\/ul>"},{"id":"924826-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Cardiovascular event risk, Reduction<\/li><li>Hypertension<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Atrial fibrillation, Recurrence; Prophylaxis - Hypertension<\/li><li>Kidney disease<\/li><li>Left ventricular hypertrophy<\/li><li>Recurrent atrial fibrillation; Prophylaxis<\/li><\/ul>"}]},"2":{"id":"924826-s-2","title":"Black Box Warning","mono":"<b>Oral (Tablet)<\/b><br\/>Drugs with direct action on the renin-angiotensin system can cause injury or death to the developing fetus. Stop therapy as soon as possible when pregnancy is detected.<br\/>"},"3":{"id":"924826-s-3","title":"Contraindications\/Warnings","sub":[{"id":"924826-s-3-9","title":"Contraindications","mono":"<ul><li>Concomitant aliskiren use in patients with diabetes<\/li><li>Hypersensitivity to telmisartan or any other component of the product<\/li><\/ul>"},{"id":"924826-s-3-10","title":"Precautions","mono":"<ul><li>Black Box Warning:<\/li><li>-- Avoid use in pregnant women; fetal and neonatal injury, including fatalities, have occurred; discontinue therapy as soon as possible when pregnancy is detected<\/li><li>Cardiovascular:<\/li><li>-- Patients with volume or salt depletion (eg, receiving high doses of diuretics) have an increased risk of symptomatic hypotension; monitoring required and dose adjustment necessary unless condition is corrected prior to initiation<\/li><li>-- Patients with severe congestive heart failure; changes in renal function, including oliguria, progressive azotemia, acute renal failure, or death have been reported<\/li><li>Endocrine and Metabolic:<\/li><li>-- Hyperkalemia may occur; increased risk with advanced renal impairment, heart failure, or patients on renal replacement therapy, potassium-sparing diuretics, potassium supplements, or potassium-containing salt substitutes; monitoring recommended<\/li><li>Hepatic:<\/li><li>-- Patients with hepatic impairment or biliary obstructive disorder may experience reduced clearance; dose adjustment necessary<\/li><li>Renal:<\/li><li>-- Patients on dialysis have an increased risk of orthostatic hypotension; monitoring recommended<\/li><li>-- Patients with renal dysfunction; changes in renal function, including oliguria, progressive azotemia, acute renal failure, or death have been reported; monitoring recommended<\/li><li>-- Patients whose renal function may depend on renin-angiotensin-aldosterone system activity; changes in renal function, including oliguria, progressive azotemia, acute renal failure, or death have been reported<\/li><li>-- Patients with unilateral or bilateral renal artery stenosis may experience increased serum creatinine or blood urea nitrogen levels<\/li><li>Concomitant Use:<\/li><li>-- Avoid concomitant use of angiotensin-receptor blockers, ACE inhibitors, or aliskiren; risk of hypotension, hyperkalemia, and renal function changes (eg, acute renal failure) increased; monitoring recommended<\/li><li>-- Avoid concomitant use of aliskiren in patients with renal impairment (GFR less than 60 mL\/min\/1.73 m(2))<\/li><li>-- Concomitant use with ramipril is not recommended<\/li><\/ul>"},{"id":"924826-s-3-11","title":"Pregnancy Category","mono":"D (FDA)<br\/>"},{"id":"924826-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"924826-s-4","title":"Drug Interactions","sub":[{"id":"924826-s-4-13","title":"Contraindicated","mono":"<ul>Aliskiren (probable)<\/ul>"},{"id":"924826-s-4-14","title":"Major","mono":"<ul><li>Benazepril (established)<\/li><li>Captopril (established)<\/li><li>Dasabuvir (theoretical)<\/li><li>Enalapril (established)<\/li><li>Enalaprilat (established)<\/li><li>Fosinopril (established)<\/li><li>Lisinopril (established)<\/li><li>Moexipril (established)<\/li><li>Ombitasvir (theoretical)<\/li><li>Paritaprevir (theoretical)<\/li><li>Perindopril (established)<\/li><li>Quinapril (established)<\/li><li>Ramipril (established)<\/li><li>Topotecan (theoretical)<\/li><li>Trandolapril (established)<\/li><li>Trimethoprim (theoretical)<\/li><\/ul>"},{"id":"924826-s-4-15","title":"Moderate","mono":"<ul><li>Aceclofenac (probable)<\/li><li>Acemetacin (probable)<\/li><li>Amtolmetin Guacil (probable)<\/li><li>Aspirin (probable)<\/li><li>Bromfenac (probable)<\/li><li>Bufexamac (probable)<\/li><li>Celecoxib (probable)<\/li><li>Choline Salicylate (probable)<\/li><li>Clonixin (probable)<\/li><li>Dexibuprofen (probable)<\/li><li>Dexketoprofen (probable)<\/li><li>Diclofenac (probable)<\/li><li>Diflunisal (probable)<\/li><li>Digoxin (probable)<\/li><li>Dipyrone (probable)<\/li><li>Etodolac (probable)<\/li><li>Etofenamate (probable)<\/li><li>Etoricoxib (probable)<\/li><li>Felbinac (probable)<\/li><li>Fenoprofen (probable)<\/li><li>Fepradinol (probable)<\/li><li>Feprazone (probable)<\/li><li>Floctafenine (probable)<\/li><li>Flufenamic Acid (probable)<\/li><li>Flurbiprofen (probable)<\/li><li>Ibuprofen (probable)<\/li><li>Ibuprofen Lysine (probable)<\/li><li>Indomethacin (probable)<\/li><li>Ketoprofen (probable)<\/li><li>Ketorolac (probable)<\/li><li>Lithium (probable)<\/li><li>Lornoxicam (probable)<\/li><li>Loxoprofen (probable)<\/li><li>Lumiracoxib (probable)<\/li><li>Meclofenamate (probable)<\/li><li>Mefenamic Acid (probable)<\/li><li>Meloxicam (probable)<\/li><li>Morniflumate (probable)<\/li><li>Nabumetone (probable)<\/li><li>Naproxen (probable)<\/li><li>Nepafenac (probable)<\/li><li>Niflumic Acid (probable)<\/li><li>Nimesulide (probable)<\/li><li>Oxaprozin (probable)<\/li><li>Oxyphenbutazone (probable)<\/li><li>Parecoxib (probable)<\/li><li>Phenylbutazone (probable)<\/li><li>Piketoprofen (probable)<\/li><li>Piroxicam (probable)<\/li><li>Proglumetacin (probable)<\/li><li>Propionic Acid (probable)<\/li><li>Propyphenazone (probable)<\/li><li>Proquazone (probable)<\/li><li>Rofecoxib (probable)<\/li><li>Salicylic Acid (probable)<\/li><li>Salsalate (probable)<\/li><li>Sodium Salicylate (probable)<\/li><li>Sulindac (probable)<\/li><li>Tenoxicam (probable)<\/li><li>Tiaprofenic Acid (probable)<\/li><li>Tolfenamic Acid (probable)<\/li><li>Tolmetin (probable)<\/li><li>Valdecoxib (probable)<\/li><\/ul>"}]},"5":{"id":"924826-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Respiratory:<\/b>Cough (1.6% to 15.6%), Upper respiratory infection (7%)<br\/><b>Serious<\/b><br\/><b>Musculoskeletal:<\/b>Rhabdomyolysis (rare)<br\/>"},"6":{"id":"924826-s-6","title":"Drug Name Info","sub":{"0":{"id":"924826-s-6-17","title":"US Trade Names","mono":"Micardis<br\/>"},"2":{"id":"924826-s-6-19","title":"Class","mono":"<ul><li>Angiotensin II Receptor Antagonist<\/li><li>Cardiovascular Agent<\/li><\/ul>"},"3":{"id":"924826-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"924826-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"924826-s-7","title":"Mechanism Of Action","mono":"<ul><li>Systemic: Telmisartan is a nonpeptide angiotensin II antagonist that selectively blocks the binding of angiotensin II to the AT 1 receptors in vascular smooth muscle and the adrenal gland . In the renin-angiotensin system, angiotensin I is converted by angiotensin-converting enzyme (ACE) to form angiotensin II . Angiotensin II stimulates the adrenal cortex to synthesize and secrete aldosterone, which decreases the excretion of sodium and increases the excretion of potassium . Angiotensin II also acts as a vasoconstrictor in vascular smooth muscle . By blocking the binding of angiotensin II to the AT 1 receptors, telmisartan causes vasodilation and decreases the effects of aldosterone . The negative feedback regulation of angiotensin II on renin secretion also is inhibited, resulting in a rise in plasma renin concentrations and a consequent rise in angiotensin II plasma concentrations; however, these effects do not counteract the blood pressure-lowering effect that occurs .<\/li><li>Telmisartan may have an inhibitory effect on cytochrome P450 2C19 isozyme and may affect the metabolism of medications that are metabolized by this enzyme .<\/li><\/ul>"},"8":{"id":"924826-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"924826-s-8-23","title":"Absorption","mono":"Systemic:  food decreases absorption.<br\/>"},"1":{"id":"924826-s-8-24","title":"Distribution","mono":"Systemic: Vd: 500 L <br\/>"},"3":{"id":"924826-s-8-26","title":"Excretion","mono":"Systemic: Fecal: &gt; 97%; Renal: &lt; 1%<br\/>"},"4":{"id":"924826-s-8-27","title":"Elimination Half Life","mono":"Systemic: 24 h.<br\/>"}}},"9":{"id":"924826-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>may be administered with or without food<\/li><li>tablets should not be removed from blisters until immediately before administration<\/li><\/ul>"},"10":{"id":"924826-s-10","title":"Monitoring","mono":"<ul><li>blood pressure<\/li><li>renal function<\/li><li>serum potassium; periodically<\/li><\/ul>"},"11":{"id":"924826-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>Oral Tablet: 20 MG, 40 MG, 80 MG<br\/><\/li><li><b>Micardis<\/b><br\/>Oral Tablet: 20 MG, 40 MG, 80 MG<br\/><\/li><\/ul>"},"13":{"id":"924826-s-13","title":"Clinical Teaching","mono":"<ul><li>Patient should avoid activities requiring coordination until drug effects are realized, as this medicine may cause dizziness.<\/li><li>Advise patient to rise slowly from sitting\/lying position as drug may cause orthostatic hypotension.<\/li><li>This drug may cause asthenia, cough, and fatigue.<\/li><li>Advise patient against sudden discontinuation of drug.<\/li><\/ul>"}}}